Navigation Links
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
Date:5/14/2008

HAYWARD, Calif., May 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that updated data will be presented on tanespimycin, the company's lead Hsp90 inhibitor, from a Phase 2 trial in combination with Herceptin(R) in patients with HER2-positive metastatic breast cancer, at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), being held at McCormick Place, Chicago, IL, May 31 through June 3, 2008.

Abstract 1027, titled, "Phase 2 trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)," will be presented in a poster session in room E450a on Tuesday, June 3, 2008 from 8:00 am through 12:00 noon CT. The presenter is Shanu Modi, M.D., of Memorial Sloan-Kettering Cancer Center. This abstract will be highlighted in a poster discussion session to be held from 11:00 am - 12:00 noon CT in room E450b.

In addition, data from a Phase 1 trial of Kosan's Hsp90 inhibitor, alvespimycin, will be presented in an oral session on Monday, June 2, 2008 at 8:00 am to 11 am CT. Abstract 2502, titled, "First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or QD," will be presented at 8:00 to 8:15 am CT in room W375a by Keith Flaherty, M.D., of the University of Pennsylvania.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development: Hsp90 (heat shock protein 90) inhibitors and epothilones. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with V
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...S, France, July 24 /- NicOx...p-line results from the 52-week,open label safety ...ion of,the 301 phase 3 study for naproxcinod. The ... efficacy was maintained for the one-year duration... assessment scale. In,addition, the results showed...
(Date:7/23/2008)...3 /- Sound Pharmaceuticals (SPI) has ... the FDA for the clinical,testing of a proprietary...otherapy induced hearing loss or ototoxicity. The ... tested in advanced stage lung cancer,and head and...motherapy.,This marks the second development progr...
(Date:7/23/2008)...s Some Areas of the Body Have Greater Concentratio...3 /PRNewswire-USNewswire/ -- Fat removed,from the ...was found to be,an excellent source of stem cells,...reas of the body, reports a Brazilian-based study ... the official medical journal of the,American Soci...
(Date:7/23/2008)... on IND-Enabling Work with Protein Therapeutics th...ement System, CAMBRIDGE, Mass., July 23 /PRNewswi...t has initiated a corporate growth plan with the,a...utive officer and the,establishment of its headqua...odruff Emlen, M.D., a co-founder of the company wh...
Breaking Medicine Technology:NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Endocare Stock to Commence Trading on NASDAQ 3184 1Endocare Stock to Commence Trading on NASDAQ 3184 2Ingenuity Systems Launches New Metabolomics Solution Within IPA 1137 1Ingenuity Systems Launches New Metabolomics Solution Within IPA 1137 2Marriage 26 Family 3A Celebrating Holiday Traditions 3178 1Marriage 26 Family 3A Celebrating Holiday Traditions 3178 2QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 1QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 2QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 3QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 4QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 5
(Date:7/25/2008)...ncial results -, LAVAL, QC, July 25 /PRNewswire-F...) today announced that it will host a conference c...ss its second quarter 2008,financial results. Labo...l,results via news release at approximately 7:00 a...by telephone, dial 416-646-3095 or,1-800-814-4859....
(Date:7/25/2008)...stCall/ -- Thoratec,Corporation (Nasdaq: THOR ) a...ry support therapies to save, support and restore ...t its operating results for the second,quarter and... 31., The company will hold a conference call to ...ties to all interested parties at 1:30 p.m.,Pacif...
(Date:7/25/2008)...unction, increases asthma risk, studies find, ,... clean, fresh-smelling home may actually be bad fo...and air freshening products you use. , Recent r...s or air fresheners that contain a certain volatil...ne (1,4 DCB), can reduce lung function by 4 percen...
(Date:7/25/2008)... Society for Gastrointestinal Endoscopy (ASGE) has... bariatric surgery patient. The rising prevalence ... surgical interventions led to a marked increase i... the U.S., from 13,365 in 1998 to 102,794 in 2003....ive patient and the postoperative patient, and app...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3
...nder affects learning have found that boys and gir...rent ways. However, they have suggested that thi...er their kids from co-educational to segregated sc...American educator Michael Gurian, at a conference ...
...co will kill a billion people this century, 10 tim... unless the countries take serious action to preve...re assuming that by putting one cigarette to your ...if you sniff-up someone else's smoke only once, yo...
...first manned mission to Mars, it has taken its fir...o you get rid of the body of a dead astronaut on a...the plug be pulled on a critically ill astronaut w...ngering the rest of the crew? Should NASA employ D...
...reveals the war veterans who have come back after ...nt. Due to the exposure to chemicals and other har...o brain regions that are closely linked to learnin...of the department of environmental health at the B...
Other Medicine News:Health News:Boys and Girls are Different by Nature and Learn in Different Ways 2Health News:1 Billion People to Be Killed by Smoking 2Health News:NASA Gets Ready To Address Tough Questions 2Health News:NASA Gets Ready To Address Tough Questions 3Health News:Gulf War Veterans Exhibit Memory Impairment 2
... IOL power calculation software. All A-scans and A...e module with SRK II, SRKT, Holladay Dioptimum and...H 5100e are equipped with corneal compression dete...eadings. The only A-Scan in the world with corneal...
The AccuSonic A-scan makes it easy to obtain extreme accuracy and improved patient outcomes. Obtain accurate measurements with industry leading signal acquisition and processing.
The UD-1000 incorporates the latest ultrasound technology for eyecare specialists. It is the ideal choice for your modern diagnostic laboratory. The UD-1000 combines a powerful B-sector scan system w
The UD-6000 combines all the functions of modern ultrasound diagnostics used in ophthalmology: The latest generation high resolution A/B-sector scanner, a diagnostic A-mode scanner with an optional p
Medicine Products: